Single and Multiple Dose Study of MK-1167 in Healthy Japanese Participants

JRCT ID: jRCT2031230399

Registered date:16/10/2023

Basic Information

• Recruitment status: Not Recruiting
• Health condition(s) or Problem(s) studied: Dementia Alzheimer's type
• Date of first enrollment: 24/10/2023
• Target sample size: 56
• Study type: Interventional
• Intervention(s): In Part 1, a single oral dose of MK-1167 3, 12 or 25 mg, or placebo will be administered. In Part 2, multiple oral doses of MK-1167 or placebo will be administered at the dose level of 22 mg on Days 1-2 and 5 mg on Days 3-10.

Outcome(s)

• Primary Outcome: Safety
• Secondary Outcome: Pharmacokinetics (Evaluation of plasma pharmacokinetics, comparison of plasma pharmacokinetics among CYP2C19 phenotypes)

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: <= 45age old
• Gender: Both
• Include criteria: Healthy Japanese males or postmenopausal females aged 18 to 45 years old
• Exclude criteria: Has a history of clinically significant abnormalities or diseases

Related Information

• Primary Sponsor: Tanaka Yoshiyuki
• Secondary ID(s): N/A